Phase 1 dose-escalation study of IV ixazomib, an investigational proteasome inhibitor, in patients with relapsed/refractory lymphoma.
about
Therapeutic options in peripheral T cell lymphomaPharmacokinetics and safety of ixazomib plus lenalidomide-dexamethasone in Asian patients with relapsed/refractory myeloma: a phase 1 studyPopulation Pharmacokinetic Analysis of Ixazomib, an Oral Proteasome Inhibitor, Including Data from the Phase III TOURMALINE-MM1 Study to Inform Labelling.Idelalisib for the treatment of non-Hodgkin lymphoma.Novel proteasome inhibitor ixazomib sensitizes neuroblastoma cells to doxorubicin treatment.The Effect of a High-Fat Meal on the Pharmacokinetics of Ixazomib, an Oral Proteasome Inhibitor, in Patients With Advanced Solid Tumors or Lymphoma.A pharmacokinetics and safety phase 1/1b study of oral ixazomib in patients with multiple myeloma and severe renal impairment or end-stage renal disease requiring haemodialysisPharmacokinetics of ixazomib, an oral proteasome inhibitor, in solid tumour patients with moderate or severe hepatic impairmentThe combination of MLN2238 (ixazomib) with interferon-alpha results in enhanced cell death in melanoma.The role of alisertib in treatment of peripheral T-cell lymphomas.Oral ixazomib maintenance therapy in multiple myeloma.Recommendations for Clinical Trial Development in Mantle Cell Lymphoma.Novel Proteasome Inhibitors and Histone Deacetylase Inhibitors: Progress in Myeloma Therapeutics.Integrated nonclinical and clinical risk assessment of the investigational proteasome inhibitor ixazomib on the QTc interval in cancer patients.Proteasomal Inhibition by Ixazomib Induces CHK1 and MYC-Dependent Cell Death in T-cell and Hodgkin Lymphoma.Double-Hit Large B Cell Lymphoma.Pharmacokinetic drug evaluation of ixazomib citrate for the treatment of multiple myeloma.A single center phase II study of ixazomib in patients with relapsed or refractory cutaneous or peripheral T-cell lymphomas.A phase I study to assess the mass balance, excretion, and pharmacokinetics of [(14)C]-ixazomib, an oral proteasome inhibitor, in patients with advanced solid tumors.The role of ixazomib as an augmented conditioning therapy in salvage autologous stem cell transplant (ASCT) and as a post-ASCT consolidation and maintenance strategy in patients with relapsed multiple myeloma (ACCoRd [UK-MRA Myeloma XII] trial): stu
P2860
Q26748857-1A89934A-2C76-4B37-BEA8-A2A66D03BBB0Q33425607-809FABA3-3749-417F-8642-16B2B1717C63Q36307049-636D7711-E0DD-48D6-B290-0EB275760C49Q37114445-9AA28BE2-8EF5-4900-8417-9FCC3E5354B8Q37298880-01474D6F-C038-48AC-AD3A-23D43FA79B39Q37348913-177FAF1B-B0DF-40F9-B930-3CF6923E5D94Q37375516-7444A3F7-B5FC-4D67-A430-38E374A22B50Q37384878-624F7E51-F17F-4CE7-9264-C5E71F3D37BBQ37697141-E3C26C9A-82FB-4F02-A9AF-EEA378228184Q38581916-E44E33C2-C9FF-49D0-89C3-D57A788B80D8Q38640514-2BEBE338-3167-4A48-A747-1966A98534A5Q39045701-BBC18A41-01BC-4131-9289-6B48ECF98F74Q39234159-E1BBBE97-0F32-4E98-B677-895D240440B9Q40770030-6578FC17-B847-44A1-8DCC-57D8AA07F181Q42320787-B2B9D984-9D63-414B-960D-17378EF4ED99Q45304558-39BD2685-64FD-40D7-A34B-DA10B471715CQ47784917-93E4334B-256B-4A17-BA14-B0DEB013C86BQ47902760-4CB92D75-8566-4ACF-83BE-C0BFA4F4502FQ48317730-E5E73C65-9D30-4979-A92C-16ACEDAD62B4Q51411892-A796AE3D-5295-4F32-AC45-E8B1A38C7D32
P2860
Phase 1 dose-escalation study of IV ixazomib, an investigational proteasome inhibitor, in patients with relapsed/refractory lymphoma.
description
2014 nî lūn-bûn
@nan
2014 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Phase 1 dose-escalation study ...... relapsed/refractory lymphoma.
@ast
Phase 1 dose-escalation study ...... relapsed/refractory lymphoma.
@en
type
label
Phase 1 dose-escalation study ...... relapsed/refractory lymphoma.
@ast
Phase 1 dose-escalation study ...... relapsed/refractory lymphoma.
@en
prefLabel
Phase 1 dose-escalation study ...... relapsed/refractory lymphoma.
@ast
Phase 1 dose-escalation study ...... relapsed/refractory lymphoma.
@en
P2093
P2860
P356
P1433
P1476
Phase 1 dose-escalation study ...... relapsed/refractory lymphoma.
@en
P2093
A Di Bacco
B D Cheson
S E Assouline
P2860
P2888
P356
10.1038/BCJ.2014.71
P577
2014-10-17T00:00:00Z
P5875
P6179
1013760776